GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Tax Provision

BOLD (Boundless Bio) Tax Provision : $0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Boundless Bio Tax Provision?

Boundless Bio's tax provision for the three months ended in Jun. 2024 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil.


Boundless Bio Tax Provision Historical Data

The historical data trend for Boundless Bio's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boundless Bio Tax Provision Chart

Boundless Bio Annual Data
Trend Dec21 Dec22 Dec23
Tax Provision
- - -

Boundless Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Boundless Bio Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Boundless Bio Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Boundless Bio Headlines

From GuruFocus